Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

• Published in: New England Journal of Medicine Vol. 386; no. 6; pp. 509 - 520
• Main Authors: Jayk Bernal, Angélica, Gomes da Silva, Monica M, Musungaie, Dany B, Kovalchuk, Evgeniy, Gonzalez, Antonio, Delos Reyes, Virginia, Martín-Quirós, Alejandro, Caraco, Yoseph, Williams-Diaz, Angela, Brown, Michelle L, Du, Jiejun, Pedley, Alison, Assaid, Christopher, Strizki, Julie, Grobler, Jay A, Shamsuddin, Hala H, Tipping, Robert, Wan, Hong, Paschke, Amanda, Butterton, Joan R, Johnson, Matthew G, De Anda, Carisa
• Format: Journal Article Web Resource
• Language: English
• Published: United States Massachusetts Medical Society 10.02.2022
• Subjects: Administration, Oral; Adolescent; Adult; Adverse events; Aged; Aged, 80 and over; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Antiviral drugs; Cardiovascular disease; Coronavirus; Coronaviruses; COVID-19; COVID-19 - virology; COVID-19 Drug Treatment; COVID-19 vaccines; Cytidine - adverse effects; Cytidine - analogs & derivatives; Cytidine - therapeutic use; Death; Diabetes; Diabetes mellitus; Double-Blind Method; Drug dosages; Enrollments; Female; Hospitalization; Humans; Hydroxylamines - adverse effects; Hydroxylamines - therapeutic use; Hypothesis testing; Immunization; Infectious Disease; Laboratories; Male; Middle Aged; Patients; Placebos; Risk factors; RNA polymerase; SARS-CoV-2 - isolation & purification; Severe acute respiratory syndrome coronavirus 2; Treatment Outcome; Viral Load; Young Adult
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2116044

Oral outpatient treatment for Covid-19 is needed. In this phase 3, double-blind, randomized, controlled trial, molnupiravir, a small-molecule antiviral, was studied in unvaccinated patients with less than 5 days of Covid-19 illness. By day 29, hospitalization for progression of Covid-19 was lower with molnupiravir (6.8%) than with placebo (9.7%).